Description
AMBLE · RESEARCH PRODUCT INFORMATION
Product overview
The supplier lists this material as Thymalin 20mg and discusses thymic-peptide and immune-regulation research. Its narrative and identity fields require formulation-specific confirmation before laboratory use; this listing does not verify equivalence to any medicinal thymic extract.
For scientific research and development only. Intended for in-vitro laboratory work, not human or animal administration. Not for use as a medicine, diagnostic product, medical device, food, supplement or cosmetic. No dosing, injection or treatment instructions are provided.
Product specifications
| Quantity | 20mg |
|---|---|
| Unit | 1 vial |
| Physical Appearance | White powder |
| Salt form | Acetate |
| Supplier reference purity (not lot verification) | ≥99% |
| Source-listed laboratory solvents | Bacteriostatic water |
Product features
- Source-listed pack: 20mg 1 vial
- Source-listed presentation: White powder
These characteristics identify the supplier reference presentation. They are not independent testing or verification of the current Amble lot.
These are reference specifications reported on the corresponding Particle Peptides page, not independent analytical verification of an Amble lot. Confirm the received label, identity, formulation and batch documentation before laboratory use. Unlisted fields have not been invented.
Identity review: the supplier narrative describes thymic-peptide material, while its structured identity fields describe a specific sequence. Those fields are not reproduced as a verified identity for this lot. Confirm the exact formulation and corresponding batch documentation.
Storage and handling
1. Research use and restrictions
For scientific research and development only. Intended for in-vitro laboratory work, not human or animal administration. Not for use as a medicine, diagnostic product, medical device, food, supplement or cosmetic. No dosing, injection or treatment instructions are provided.
Literature involving animals or clinical studies is background information only and does not authorize this product for those uses. Do not supply this material for human investigational use.
2. Peptides in transport
Follow the current product label and lot-specific transport documentation. A general supplier statement about transport stability is not a guarantee for every formulation, liquid, blend or Amble shipment. The source supplier lists shipping restrictions for: Canada, Croatia, Czech Republic, Iceland, Ireland, Luxemburg, Norway, Serbia, Switzerland. This is the supplier’s published list, not a complete legal assessment or a replacement for Amble’s shipping policy.
3. Storage of lyophilized peptides
The supplier gives general guidance to protect lyophilized peptides from light and moisture. Storage temperature and expiry must follow the actual formulation and lot documentation. Do not treat a generic storage-duration table as validated shelf-life data for this Amble product.
4. Storage of reconstituted peptides
Solution stability depends on sequence, formulation, solvent and handling. Use product-specific stability documentation and laboratory procedures rather than assuming the same refrigerated life for all peptides. The supplier’s Ipamorelin stability discussion cannot be extrapolated to other products without supporting data.
5. Storage of peptide solutions
Avoid unnecessary freeze–thaw cycling and follow the documented conditions for the exact solution. This page does not establish a validated shelf life after preparation. The listed solvent information is a supplier reference, not a patient-use or injection protocol.
Overview of published research
The corresponding source page discusses the topics below. They describe areas of investigation, not proven customer benefits, treatment indications or evidence that this particular Amble batch has been tested.
- Thymic-peptide and immune-regulation literature
- Gene-expression and cellular-response studies
- Formulation-specific identity and characterization
Interpretation depends on the study design, experimental material and model. The presence of a publication in a supplier bibliography is not an independent verification of the supplier’s interpretation or a guarantee of safety or effectiveness. No clinical doses or administration protocols are reproduced here.
Quality and documentation
Source attribution: the specifications and bibliography below refer to Particle Peptides. Amble branding does not turn the supplier’s studies or documents into Amble batch certifications.
View the corresponding supplier product page
- Supplier safety data sheet (MSDS)
- Supplier COA/test document — not verification of the current Amble lot
Document links are retained as supplier references. Confirm lot matching, document authenticity and applicability before relying on them; this update does not independently verify those documents.
Bibliography listed by the supplier (26 entries)
Bibliographic entries are attributed to the source page. Individual citations have not all been independently validated; consult the original publications and distinguish primary studies from secondary reports.
- V. K. Khavinson et al., “The Use of Thymalin for Immunocorrection and Molecular Aspects for Biological Activity”, 2021.
- V. K. Khavinson and V. G. Morozov, “Peptides of pineal gland and thymus prolong human life,” Neuro Endocrinol. Lett., vol. 24, no. 3–4, pp. 233–240, Aug. 2003.
- V. K. Khavinson and V. G. Morozov, “[Geroprotective effect of thymalin and epithalamin],” Adv. Gerontol. Uspekhi Gerontol., vol. 10, pp. 74–84, 2002.
- N. S. Lin’kova, V. O. Poliakova, I. M. Kvetnoĭ, A. V. Trofimov, and N. N. Sevost’ianova, “[Characteristics of the pineal gland and thymus relationship in aging],” Adv. Gerontol. Uspekhi Gerontol., vol. 24, no. 1, pp. 38–42, 2011.
- J. Bach, M. Bardenne, J. Pleau, and J. Rosa, “Biochemical characterisation of a serum thymic factor,” Nature, vol. 266, no. 5597, pp. 55–57, Mar. 1977.
- A. M. Reznichenko, V. P. Fesenko, D. V. Shestopalov, and P. A. Tatarchuk, “[Changes in cell immunity indexes under the influence of thymalin, thyroxine and fibronectin in patients with hyperplastic diseases of thyroid gland before and after the surgery],” Klin. Khir., no. 12, pp. 31–33, Dec. 2001.
- H. D. Zhaboiedov, N. H. Bychkova, R. L. Skrypnik, and M. V. Sydorova, “[Evaluation of cellular and humoral immunity and individual sensitivity of T-lymphocytes to immunocorrectors in patients with diabetic retinopathy],” Lik. Sprava, no. 1, pp. 53–56, Feb. 2001.
- T. P. Young, “Immune mechanisms in HIV infection,” J. Assoc. Nurses AIDS Care JANAC, vol. 14, no. 6, pp. 71–75, Dec. 2003.
- E. Montomoli, S. Piccirella, B. Khadang, E. Mennitto, R. Camerini, and A. De Rosa, “Current adjuvants and new perspectives in vaccine formulation,” Expert Rev. Vaccines, vol. 10, no. 7, pp. 1053–1061, Jul. 2011.
- I. I. Hrinevych, H. D. Bendiuh, N. M. Khranovs’ka, I. M. Bilokin’, and O. M. Ostapenko, “[Effect of thyroxin and thymalin on proliferation and apoptosis of thymocytes in rats after thyroidectomy],” Fiziolohichnyi Zhurnal Kiev Ukr. 1994, vol. 50, no. 3, pp. 39–43, 2004.
- A. P. Kozlov and K. G. Moskalik, “Pulsed laser radiation therapy of skin tumors,” Cancer, vol. 46, no. 10, pp. 2172–2178, Nov. 1980.
- R. I. Wagner, A. P. Kozlov, and K. G. Moskalik, “Laser radiation therapy of skin melanoma,” Strahlentherapie, vol. 157, no. 10, pp. 670–672, Oct. 1981.
- K. G. Moskalik, “[Effect of thymalin and epithalamin on the metastasis of experimental tumors irradiated with pulsed laser radiation],” Vopr. Onkol., vol. 33, no. 1, pp. 57–62, 1987.
- G. V. Zhukova, A. I. Schikhlyarova, T. A. Barteneva, A. N. Shevchenko, and F. M. Zakharyuta, “Effect of Thymalin on the Tumor and Thymus under Conditions of Activation Therapy In Vivo,” Bull. Exp. Biol. Med., vol. 165, no. 1, pp. 80–83, May 2018.
- N. N. Tretiak, T. F. Babenko, S. N. Gaĭdukova, A. S. Zverkova, and S. P. Beschastnaia, “[The efficacy of using thymalin and plasmapheresis in the combined treatment of patients with chronic lympholeukemia],” Lik. Sprava, no. 2, pp. 93–96, Apr. 1998.
- T. F. Babenko, V. T. Antonenko, and M. F. SkuratovskiUi, “[Thymalin in the combined treatment of patients with chronic lympholeukemia],” Vrach. Delo, no. 3, pp. 47–49, Mar. 1989.
- M. P. Isaeva, G. B. Budazhabon, and B. I. Kuznik, “[The effect of thymalin on indices of immunity and hemostasis in patients with disseminated forms of psoriasis],” Vestn. Dermatol. Venerol., no. 10, pp. 42–43, 1989.
- A. A. Maslennikov, V. F. Kamenev, and V. M. Kolomiets, “[Immunological correction in progressive pulmonary tuberculosis],” Probl. Tuberk. Bolezn. Legk., no. 9, pp. 30–33, 2007.
- L. A. Ivanova, “[The use of thymalin in the combined chemotherapy of patients with infiltrative destructive pulmonary tuberculosis],” Vrach. Delo, no. 10, pp. 57–59, Oct. 1989.
- M. A. Karachunskiĭ, V. I. Gergert, and O. B. Iakovleva, “[Specific features of cellular immunity of pulmonary tuberculosis in patients with diabetes mellitus],” Probl. Tuberk., no. 6, pp. 59–60, 1997.
- G. V. Budazhabon, B. I. Kuznik, V. G. Morozov, N. N. Orlova, and V. K. Khavinson, “[Immunogenesis and hemostasis in patients with exacerbated chronic glomerulonephritis treated with thymalin],” Ter. Arkh., vol. 56, no. 10, pp. 62–66, 1984.
- I. F. Labunets’, “[Age-related changes in circadian and circannual fluctuations of the immune response and the number of cells in lymphoid organs of animals: a possible connection to thymic factors],” Fiziolohichnyi Zhurnal Kiev Ukr. 1994, vol. 47, no. 5, pp. 54–62, 2001.
- V. E. Ryzhenkov, R. P. Ogurtsov, V. V. Trubacheva, V. G. Popov, and V. P. Puzyreva, “[Effect of thymalin on the development of experimental hyperlipidemia and atherosclerosis],” Vopr. Med. Khim., vol. 34, no. 1, pp. 51–56, Feb. 1988.
- 2Z. S. Zhumadilov and R. P. Terekhova, “[Use of thymalin for preventing postoperative suppurative and inflammatory complications],” Klin. Khirurgiia, no. 1, pp. 36–38, Jan. 1985.
- B. I. Kuznik, V. K. Khavinson, V. G. Morozova, G. B. Budazhabon, and N. G. Budazhabon, “[Use of thymalin in treating periodontitis patients],” Stomatologiia (Sofiia), vol. 64, no. 1, pp. 20–22, Feb. 1985.
- S. Wade et al., “Thymulin (Zn-facteur thymique serique) activity in anorexia nervosa patients,” Am. J. Clin. Nutr., vol. 42, no. 2, pp. 275–280, Aug. 1985.
Product questions and answers
What is Thymalin 20mg?
The supplier lists this material as Thymalin 20mg and discusses thymic-peptide and immune-regulation research. Its narrative and identity fields require formulation-specific confirmation before laboratory use; this listing does not verify equivalence to any medicinal thymic extract.
What quantity is listed for Thymalin 20mg?
The corresponding supplier reference lists 20mg 1 vial. This applies to the stated presentation only; other strengths and quantities are not included.
Which identity or formulation details matter for Thymalin 20mg?
The supplier’s narrative and structured identity fields require formulation-specific reconciliation. Sequence, molecular mass and CAS identity are not presented here as verified for an Amble lot.
Does the linked documentation certify this Amble batch?
No Amble-lot certification is established by a supplier webpage or an unmatched COA. Confirm the laboratory report, exact batch number, identity and formulation before relying on the documentation.
What storage conditions are verified for Thymalin 20mg?
Follow the actual lot label and product-specific safety and stability documentation. Generic storage tables and studies on another peptide do not establish this product’s shelf life.
Is Thymalin 20mg intended for human use?
No. This is a research-use listing for in-vitro laboratory work, not human or animal administration. The page provides no dosing, injection or treatment instructions.
US online ordering information
Information for customers reviewing Thymalin 20mg online from the United States.
This is a research-use listing, not a patient treatment or a finished medicine. Do not use it for human or animal administration. Review the exact formulation and lot-matched documentation, and confirm jurisdiction-specific eligibility before placing any order.
Use the live price and stock display on this page and review the final checkout total. Delivery, tax and return conditions depend on the product and destination; do not assume a delivery date or eligibility from this page alone.
For product or ordering questions, email hello@joinamblehealth.com. Read the Amble terms of service or visit your Amble account.
Reviews
There are no reviews yet.